160 related articles for article (PubMed ID: 34297961)
21. Economic evaluation of rotavirus vaccination in children of Bhutan.
Pempa ; Luz ACG; Luangasanatip N; Kingkaew P; Adhikari D; Isaranuwatchai W; Choiphel D; Pecenka C; Debellut F
Vaccine; 2020 Jul; 38(32):5049-5059. PubMed ID: 32522415
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
[TBL] [Abstract][Full Text] [Related]
24. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
[TBL] [Abstract][Full Text] [Related]
25. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
26. Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines.
Debellut F; Tang K; Clark A; Pecenka C; Assao B; Guindo O; Grais RF; Isanaka S
BMJ Open; 2022 Oct; 12(10):e061673. PubMed ID: 36198460
[TBL] [Abstract][Full Text] [Related]
27. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.
Cui S; Tobe RG; Mo X; Liu X; Xu L; Li S
BMC Infect Dis; 2016 Nov; 16(1):677. PubMed ID: 27846803
[TBL] [Abstract][Full Text] [Related]
30. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
Rheingans R; Atherly D; Anderson J
Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
[TBL] [Abstract][Full Text] [Related]
33. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684685
[TBL] [Abstract][Full Text] [Related]
34. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
[TBL] [Abstract][Full Text] [Related]
35. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan.
Anwari P; Debellut F; Pecenka C; Parwiz SM; Clark A; Groman D; Safi N
Vaccine; 2018 Dec; 36(51):7769-7774. PubMed ID: 29107346
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.
Kanungo S; Chatterjee P; Bavdekar A; Murhekar M; Babji S; Garg R; Samanta S; Nandy RK; Kawade A; Boopathi K; Kanagasabai K; Kamal VK; Kumar VS; Gupta N; Dutta S
Lancet Infect Dis; 2022 Aug; 22(8):1191-1199. PubMed ID: 35588754
[TBL] [Abstract][Full Text] [Related]
37. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain.
Pérez-Rubio A; Luquero FJ; Eiros Bouza JM; Castrodeza Sanz JJ; Bachiller Luque MR; de Lejarazu RO; Sánchez Porto A
Infez Med; 2011 Sep; 19(3):166-75. PubMed ID: 22037437
[TBL] [Abstract][Full Text] [Related]
38. Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?
Deen J; Lopez AL; Kanungo S; Wang XY; Anh DD; Tapia M; Grais RF
Hum Vaccin Immunother; 2018 Feb; 14(2):495-499. PubMed ID: 29135339
[TBL] [Abstract][Full Text] [Related]
39. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh.
Pecenka C; Parashar U; Tate JE; Khan JAM; Groman D; Chacko S; Shamsuzzaman M; Clark A; Atherly D
Vaccine; 2017 Jul; 35(32):3982-3987. PubMed ID: 28623028
[TBL] [Abstract][Full Text] [Related]
40. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
